Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurodegenerative and Metabolic Disease Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for SLC52A2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SLC52A2 Full-Length Membrane Protein (Detergent Solubilized) High purity (>90%), Sequence Verified. Ideal for ELISA and binding assays. |
View SLC52A2 Products |
| Gene Delivery | SLC52A2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and functional uptake assays. |
View SLC52A2 Products |
| Benchmark Ab | Anti-SLC52A2 Recombinant Antibody Sequence-verified positive control for IHC, Western Blot, and Flow Cytometry. |
View SLC52A2 Products |
| Validator | SLC52A2 siRNA Set For knockdown verification in riboflavin transport assays. |
View SLC52A2 Products |
| Related Target A | SLC52A3 Riboflavin Transporter 3. Critical for subfamily selectivity and off-target screening. |
View SLC52A3 Products |
| Related Target B | SLC52A1 Riboflavin Transporter 1. Closely related homolog used for tissue-specificity profiling. |
View SLC52A1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass (10-TM) membrane conformation preservation | Lentivirus delivery for stable cell line generation to enable native cell-based functional assays. |
| Subfamily cross-reactivity (SLC52A1/A3) | Sequence-verified recombinant proteins and custom cell lines for parallel selectivity screening. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) and validated controls included. |
| False Positives | Validated siRNA included for specificity checks. |
Live SLC52A2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SLC52A2 therapeutics is intensifying, with major players shifting focus from traditional small molecules to gene therapy and targeted metabolic modulation. As first-generation therapies for riboflavin transporter deficiencies reach the clinic, the next wave of R&D is targeting cancer metabolism and selective transporter inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV) | Orphan Drug Developers, Academic Consortia | Brown-Vialetto-Van Laere Syndrome 2 (BVVL2) | Functional rescue assays (Need high-titer Lentivirus for stable cell lines) |
| Small Molecule Chaperones | Rare Disease Biotechs | Riboflavin Transporter Deficiency (RTD) | Uptake kinetics and transport restoration assays (Need validated siRNA/overexpression) |
| Small Molecule Inhibitors | Oncology Biopharma | Metabolic-dependent Solid Tumors | Selectivity assays (Need SLC52A1/A2/A3 recombinant protein panel) |